Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49,625,327
-
Total 13F shares
-
5,478,268
-
Share change
-
+57,638
-
Total reported value
-
$7,437,200
-
Price per share
-
$1.35
-
Number of holders
-
20
-
Value change
-
+$69,457
-
Number of buys
-
7
-
Number of sells
-
8
Institutional Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q1 2023
As of 31 Mar 2023 Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) had 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 5,478,268 shares of stock of the company.
Largest 10 holders included Northpond Ventures, LLC, FRANKLIN RESOURCES INC, Sands Capital Ventures, LLC, FMR LLC, VANGUARD GROUP INC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, Baystate Wealth Management LLC, CITADEL ADVISORS LLC, and BlackRock Inc..
This table shows 20 institutional shareholders of the security as of 31 Mar 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.